March 06, 2026VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. March 05, 2026VOLUNTARY ANNOUNCEMENT - INDACATEROL ACETATE AND MOMETASONE FUROATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA March 04, 2026VOLUNTARY ANNOUNCEMENT - EMICIZUMAB INJECTION (SYS6053) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA March 02, 2026VOLUNTARY ANNOUNCEMENT - PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION, RAPID SUSPENSION (ALBUMIN-BOUND) (SYHX2011G1) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. March 02, 2026LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION March 02, 2026APPOINTMENT OF AN EXECUTIVE DIRECTOR February 26, 2026CONNECTED TRANSACTION - DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY February 16, 2026VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE LONG-ACTING INJECTION (SYH2082 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. February 16, 2026VOLUNTARY ANNOUNCEMENT - ROPIVACAINE LONG-ACTING INJECTION (SYH9089 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA February 02, 2026VOLUNTARY ANNOUNCEMENT - CLEVIDIPINE INJECTABLE EMULSION OBTAINS DRUG REGISTRATION APPROVAL January 30, 2026VOLUNTARY ANNOUNCEMENT - ENTERING INTO A STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR THE DEVELOPMENT OF INNOVATIVE LONG-ACTING PEPTIDE MEDICINES January 29, 2026VOLUNTARY ANNOUNCEMENT - SYS6055 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA January 23, 2026VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY January 15, 2026INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2025 January 13, 2026VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. January 12, 2026VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS January 02, 2026VOLUNTARY ANNOUNCEMENT - NINTEDANIB ESILATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA